CD274 and gastric cancer: A global phase 3 trial (CheckMate-649) recently found that the combination of nivolumab and chemotherapy (FOLFOX or capecitabine plus oxaliplatin) conferred a significant survival benefit in previously untreated patients with advanced GC in a manner dependent on PD-L1 expression level [37].